Interferon-alpha (IFN-α) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte turnout cultures (MLTC)

Clinical and Experimental Immunology

Volumn 119, Issue 3, 2000, Pages 412-418

  Palmer, K J ^a   Harries, M ^a   Gore, M E ^b   Collins, M K L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic; IFN ; T cell melanoma

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; MELANOMA; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

EID: 0034020397     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01159.x     Document Type: Article

References (28)

1. 1 Bridgewater JA, Gore ME. Biological response modifiers in melanoma. Br Med Bull 1995; 51:656-77.
2. 2 Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
3. 3 Rhodes J, Ivanyi J, Cozens P. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur J Immunol 1986; 16:370-5.
4. 4 Niederwieser D, Aubock J, Troppmair J et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 1988; 140:2556-64.
5. 5 Lapierre LA, Fiers W, Pober JS. Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons. J Exp Med 1988; 167:794-804.
6. 6 Halloran PF, Urmson J, Van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues. J Immunol 1989; 142:4241-7.
7. 7 Giacomini P, Fraioli R, Calabro AM, Di Filippo F, Natali PG. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res 1991; 51:652-6.
8. 8 Giacomini P, Gambari R, Barbieri R et al. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons. Anticancer Res 1986; 6:877-84.
9. 9 Nistico P, Tecce R, Giacomini P, Cavallari A, D'Agnano I, Fisher PB, Natali PG. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 1990; 50:7422-9.
10. 10 Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272:1947-50.
11. 11 Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4 + T cells. J Exp Med 1993; 178:1655-63.
12. 12 Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999; 162:2399-405.
13. 13 Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18:267-8.
14. 14 Ikeda H, Lethe B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6:199-208.
15. 15 Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173:1373-84.
16. 16 Ferrantini M, Giovarelli M, Modesti A et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8 + T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994; 153:4604-15.
17. 17 Coleman M, Muller S. Quezada A et al. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998; 9:2223-30.
18. 18 Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, Sprent J, Tough DF. The induction of in vivo proliferation of long-lived CD44hi CD8 + T cells after the injection of tumor cells expressing IFN-alpha 1 into syngeneic mice. Cancer Res 1998; 58:5795-802.
19. 19 Palmer K, Moore J, Everard M et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999; 10:1261-8.
20. 20 Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992; 50:289-97.
21. 21 De Wit D, Flemming CL, Harris JD, Palmer KJ, Moore JS, Gore ME, Collins MK. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1996; 105:353-9.
22. 22 Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Giovarelli M, Lalli E, Facchini A, Lollini PL. Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon. Br J Cancer 1992; 66:479-82.
23. 23 Carson WE. IFN-alpha-induced activation of STATs in malignant melanoma. Clin Cancer Res 1998; 4:2219-28.
24. 24 Tuting T, Wilson CC, Martin DM et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998; 160:1139-47.
25. 25 Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-60.
26. 26 Hakansson A, Gustafsson B, Krysander L, Bergenwald C, Sander B, Hakansson L. Effect of IFN-alpha on the expression of TNF-alpha by metastatic melanoma patients. Melanoma Res 1997; 7:139-45.
27. 27 Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 1998; 28:2384-94.
28. 28 Hakem R, Le Bouteiller P, Jezo-Bremond A, Harper K, Campese D, Lemonnier FA. Differential regulation of HLA-A3 and HLA-B7 MHC class I genes by IFN is due to two nucleotide differences in their IFN response sequences. J Immunol 1991; 147:2384-90.